Kura Oncology, Inc.
KURADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How KURA's past catalysts played out
Ziftomenib
Acute Myeloid Leukemia (AML)
Tipifarnib
HNSCC
Midazolam
Advanced Malignant Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ziftomenib | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Tipifarnib | Phase 2 | HNSCC | - | - |
Midazolam | Phase 2 | Advanced Malignant Neoplasm | - | - |
Advanced Malignant Neoplasm
1 drug in this indication
HNSCC
1 drug in this indication
Acute Myeloid Leukemia (AML)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Kura Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Kura Oncology, Inc.'s (KURA) pipeline across Phase 3, Phase 2. Its lead program is Ziftomenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kura Oncology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Kura Oncology, Inc. (KURA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KURA biotech catalysts?→
Add KURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kura Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.